Monitoring patient response to therapeutics comes with a need to follow certain assessment and testing protocols.
Conventional central laboratory testing programs can be lengthy, possibly causing anxiety for patients and unnecessarily using up vital funds.
Diagnostic testing linked with pharmaceutical therapies and vaccines is increasing as public and private health budget managers seek to demonstrate the efficacy and value of chosen therapies.
Abingdon Health’s pedigree in lateral flow development and ability to assume legal manufacturer status on behalf of its customers expedites the development, manufacture and launch of a near-patient test. This presents a time and cost-efficient route to market and a long term assurance of post launch product support and continuity of supply.